Notice of Development of Set 23 Toxicological Profiles, 36493-36494 [E9-17527]
Download as PDF
36493
Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices
The following draft toxicological
profile will be made available to the
public on or about July 6, 2009.
Document
Toxicological profile
CAS No.
1 .................................................................
PERFLUOROALKYLS ..................................................................................................
000375–22–4
000335–67–1
001763–23–1
All profiles issued as ‘‘Draft for Public
Comment’’ represent ATSDR’s best
efforts to provide important
toxicological information on priority
substances. We are seeking public
comments and additional information
that may be used to supplement this
profile. ATSDR remains committed to
providing a public comment period for
these documents as the best means to
serve public health and our clients.
Ken Rose,
Director, Office of Policy, Planning, and
Evaluation, National Center for
Environmental Health/Agency for Toxic
Substances and Disease Registry.
[FR Doc. E9–17529 Filed 7–22–09; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[ATSDR–254]
Notice of Development of Set 23
Toxicological Profiles
AGENCY: Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Notice.
consists of three new drafts and two
updated drafts. These profiles will be
available to the public on or about
October 17, 2009. Electronic access to
these documents will be available at the
ATSDR Web site: https://
www.atsdr.cdc.gov/toxpro2.html.
Set 23 Toxicological Profiles
The following toxicological profiles
are now being developed:
SUMMARY: This notice announces the
development of Set 23 Toxicological
Profiles. Set 23 Toxicological Profiles
Toxicological profile
1.
2.
3.
4.
CAS No.
Acrylamide* ......................................................................................................................................
Carbon Monoxide* ...........................................................................................................................
1,3-Butadiene ..................................................................................................................................
Phosphate Ester Flame Retardants* ...............................................................................................
5. Vanadium .........................................................................................................................................
79–06–1
630–08–0
106–99–0
126–73–8, 126–71–6, 78–51–3, 115–86–6,
13674–84–5, 13674–87–8, 115–96–8
7440–62–2
* Denotes new profile.
The
Superfund Amendments and
Reauthorization Act of 1986 (SARA) (42
U.S.C. 9601 et seq.) amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) (42
U.S.C. 9601 et seq.) by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) with regard to hazardous
substances that are most commonly
found at facilities on the CERCLA
National Priorities List (NPL). Among
these statutory requirements is a
mandate for the Administrator of
ATSDR to prepare toxicological profiles
for each substance included on the
Priority List of Hazardous Substances
(https://www.atsdr.cdc.gov/cercla/
07list.html). This list names 275
hazardous substances that pose the most
significant potential threat to human
health as determined by ATSDR and
EPA. The availability of the revised list
of the 275 priority substances was
erowe on DSK5CLS3C1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Nov<24>2008
15:01 Jul 22, 2009
Jkt 217001
announced in the Federal Register on
March 6, 2008 (73 FR 12178). For prior
versions of the list of substances, see
Federal Register notices dated April 17,
1987 (52 FR 12866); October 20, 1988
(53 FR 41280); October 26, 1989 (54 FR
43619); October 17, 1990 (55 FR 42067);
October 17, 1991 (56 FR 52166); October
28, 1992 (57 FR 48801); February 28,
1994 (59 FR 9486); April 29, 1996 (61
FR 18744; November 17, 1997 (62 FR
61332); October 21, 1999 (64 FR 56792);
October 25, 2001 (66 FR 54014);
November 7, 2003 (68 FR 63098); and
December 7, 2005 (70 FR 70284).
The Set 23 Toxicological Profiles for
1,3-Butadiene and Vanadium are
updates of previously published profiles
for NPL priority substances. In addition,
to address emerging public health
concerns related to substances not
currently on the NPL, ATSDR is also
developing Set 23 Toxicological Profiles
for Carbon Monoxide, Acrylamide, and
Phosphate Ester Flame Retardants.
Carbon monoxide is a toxic gas
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
produced from the incomplete
combustion of carbon-based fuels.
Because it is colorless and odorless,
toxicity can occur with no indication
that exposure is occurring. Thousands
of hospitalizations and hundreds of
deaths occur every year as a result of
inadvertent exposure to carbon
monoxide. Acrylamide is a known
animal carcinogen that is widely used in
industry to synthesize polyacrylamides.
Acrylamide also occurs naturally in a
few foods, is formed in many foods as
a byproduct of numerous cooking
processes, and has been detected
recently in human biomonitoring
studies. Phosphate ester flame
retardants comprise a large group of
structurally related chemicals with
increasing uses in clothing, fabrics,
furniture, and structural components.
However, there is an increasing body of
information regarding exposures, body
burdens, and toxicity related to this
group of chemicals.
E:\FR\FM\23JYN1.SGM
23JYN1
36494
Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices
Notice of the availability of drafts of
these two updated and three new
toxicological profiles for public review
and comment will be published in the
Federal Register on/or about October
17, 2009, with notice of a 90-day public
comment period for each profile,
starting from the actual release date.
Following the close of the comment
period, chemical-specific comments
will be addressed, and, where
appropriate, changes will be
incorporated into each profile.
FOR FURTHER INFORMATION CONTACT:
Commander Jessilynn B. Taylor,
Division of Toxicology and
Environmental Medicine, Agency for
Toxic Substances and Disease Registry,
1600 Clifton Road, NE., Mail Stop F–32,
Atlanta, GA 30333, telephone 770–488–
3313.
Ken Rose,
Director, Office of Policy, Planning and
Evaluation, National Center for
Environmental Health/Agency for Toxic
Substances and Disease Registry.
[FR Doc. E9–17527 Filed 7–22–09; 8:45 am]
contract proposals relating to the broad areas
within the national center.
Matters To Be Discussed: The board will
perform a secondary review of previously
rated grant applications received by NCPHI
based on RFA–HK–09–001; Centers of
Excellence in Public Health Informatics (P01)
and reviewed by an expert panel convened
by NCPHI on July 22—24, 2009.
Contact Person for More Information: Dr.
Scott McNabb, National Center for Public
Health Informatics, CDC, 1600 Clifton Road,
NE., (E–78), Atlanta, Georgia 30333,
Telephone (404) 498–6427, Fax (404) 498–
6235.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and the Agency for Toxic
Substance and Disease Registry.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: July 17, 2009.
Elaine L. Baker,
Management Analysis and Services Office,
Centers for Disease Control and Prevention.
[FR Doc. E9–17524 Filed 7–22–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: July 16, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–17430 Filed 7–22–09; 8:45 am]
BILLING CODE 4140–01–P
Centers for Disease Control and
Prevention
BILLING CODE 4160–18–P
Clinical Laboratory Improvement
Advisory Committee (CLIAC); Meeting
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
National Institute of Mental Health;
Notice of Closed Meeting
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Public Health
Informatics (BSC, NCPHI)
erowe on DSK5CLS3C1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Time and Date: 1 p.m.–5 p.m., August 7,
2009 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Purpose: The committee shall advise the
Secretary, HHS, and the Director, CDC,
concerning strategies and goals for the
programs and research within the national
centers; shall conduct peer-review of
scientific programs; and monitor the overall
strategic direction and focus of the national
centers. The board, after conducting its
periodic reviews, shall submit a written
description of the results of the review and
its recommendations to the Director, CDC.
The board shall perform second-level peer
review of applications for grants-in-aid for
research and research training activities,
cooperative agreements, and research
VerDate Nov<24>2008
15:01 Jul 22, 2009
Jkt 217001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel, HIV
Exploratory Applications.
Date: July 28, 2009.
Time: 11 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Enid Light, PhD, Scientific
Review Officer, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center, 6001
Executive Boulevard, Room 6132, MSC 9608,
Bethesda, MD 20852–9608, 301–443–0322,
elight@mail.nih.gov.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Times and Dates:
8:30 a.m.–5 p.m., September 2, 2009.
8:30 a.m.–3 p.m., September 3, 2009.
Place: CDC, 1600 Clifton Road, NE., Tom
Harkin Global Communications Center,
Building 19, Room 232, Auditorium B,
Atlanta, Georgia 30333.
New Information—Online Registration
Required: In order to expedite the security
clearance process at the CDC Roybal Campus
located on Clifton Road, all CLIAC attendees
are required to register for the meeting online
at least 14 days in advance at https://
wwwn.cdc.gov/cliac/default.aspx by clicking
the ‘‘Register for a Meeting’’ link and
completing all forms according to the
instructions given. Please complete all the
required fields before submitting your
registration and submit no later than August
19, 2009.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
Purpose: This Committee is charged with
providing scientific and technical advice and
guidance to the Secretary of Health and
Human Services, the Assistant Secretary for
Health, and the Director, CDC, regarding the
need for, and the nature of, revisions to the
standards under which clinical laboratories
are regulated; the impact on medical and
laboratory practice of proposed revisions to
the standards; and the modification of the
standards to accommodate technological
advances.
Matters To Be Discussed: The agenda will
include agency updates from the CDC, the
Centers for Medicare & Medicaid Services,
E:\FR\FM\23JYN1.SGM
23JYN1
Agencies
[Federal Register Volume 74, Number 140 (Thursday, July 23, 2009)]
[Notices]
[Pages 36493-36494]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-17527]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[ATSDR-254]
Notice of Development of Set 23 Toxicological Profiles
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the development of Set 23 Toxicological
Profiles. Set 23 Toxicological Profiles consists of three new drafts
and two updated drafts. These profiles will be available to the public
on or about October 17, 2009. Electronic access to these documents will
be available at the ATSDR Web site: https://www.atsdr.cdc.gov/toxpro2.html.
Set 23 Toxicological Profiles
The following toxicological profiles are now being developed:
----------------------------------------------------------------------------------------------------------------
Toxicological profile CAS No.
----------------------------------------------------------------------------------------------------------------
1. Acrylamide*............................... 79-06-1
2. Carbon Monoxide*.......................... 630-08-0
3. 1,3-Butadiene............................. 106-99-0
4. Phosphate Ester Flame Retardants*......... 126-73-8, 126-71-6, 78-51-3, 115-86-6, 13674-84-5, 13674-87-8,
115-96-8
5. Vanadium.................................. 7440-62-2
----------------------------------------------------------------------------------------------------------------
* Denotes new profile.
SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization
Act of 1986 (SARA) (42 U.S.C. 9601 et seq.) amended the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA
or Superfund) (42 U.S.C. 9601 et seq.) by establishing certain
requirements for ATSDR and the U.S. Environmental Protection Agency
(EPA) with regard to hazardous substances that are most commonly found
at facilities on the CERCLA National Priorities List (NPL). Among these
statutory requirements is a mandate for the Administrator of ATSDR to
prepare toxicological profiles for each substance included on the
Priority List of Hazardous Substances (https://www.atsdr.cdc.gov/cercla/07list.html). This list names 275 hazardous substances that pose the
most significant potential threat to human health as determined by
ATSDR and EPA. The availability of the revised list of the 275 priority
substances was announced in the Federal Register on March 6, 2008 (73
FR 12178). For prior versions of the list of substances, see Federal
Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988
(53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR
42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801);
February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744; November
17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); October 25,
2001 (66 FR 54014); November 7, 2003 (68 FR 63098); and December 7,
2005 (70 FR 70284).
The Set 23 Toxicological Profiles for 1,3-Butadiene and Vanadium
are updates of previously published profiles for NPL priority
substances. In addition, to address emerging public health concerns
related to substances not currently on the NPL, ATSDR is also
developing Set 23 Toxicological Profiles for Carbon Monoxide,
Acrylamide, and Phosphate Ester Flame Retardants. Carbon monoxide is a
toxic gas produced from the incomplete combustion of carbon-based
fuels. Because it is colorless and odorless, toxicity can occur with no
indication that exposure is occurring. Thousands of hospitalizations
and hundreds of deaths occur every year as a result of inadvertent
exposure to carbon monoxide. Acrylamide is a known animal carcinogen
that is widely used in industry to synthesize polyacrylamides.
Acrylamide also occurs naturally in a few foods, is formed in many
foods as a byproduct of numerous cooking processes, and has been
detected recently in human biomonitoring studies. Phosphate ester flame
retardants comprise a large group of structurally related chemicals
with increasing uses in clothing, fabrics, furniture, and structural
components. However, there is an increasing body of information
regarding exposures, body burdens, and toxicity related to this group
of chemicals.
[[Page 36494]]
Notice of the availability of drafts of these two updated and three
new toxicological profiles for public review and comment will be
published in the Federal Register on/or about October 17, 2009, with
notice of a 90-day public comment period for each profile, starting
from the actual release date. Following the close of the comment
period, chemical-specific comments will be addressed, and, where
appropriate, changes will be incorporated into each profile.
FOR FURTHER INFORMATION CONTACT: Commander Jessilynn B. Taylor,
Division of Toxicology and Environmental Medicine, Agency for Toxic
Substances and Disease Registry, 1600 Clifton Road, NE., Mail Stop F-
32, Atlanta, GA 30333, telephone 770-488-3313.
Ken Rose,
Director, Office of Policy, Planning and Evaluation, National Center
for Environmental Health/Agency for Toxic Substances and Disease
Registry.
[FR Doc. E9-17527 Filed 7-22-09; 8:45 am]
BILLING CODE 4163-70-P